FDA Accepts Nanoscopes's Optogenetic Gene Therapy BLA

The FDA accepts a biologics license application (BLA) for a first-of-its-kind optogenetic gene therapy for RP; a software upgrade from Heru combines several pretesting assessments into a single guided workflow; and a new FDA-approved overnight orthokeratology lens is launched in the US.

Learn more about your ad choices. Visit megaphone.fm/adchoices